Viking Therapeutics
Open
$28.85
Prev. Close
$28.92
High
$28.88
Low
$28.73
Market Snapshot
$3.32B
-7.0
-1.00
59
Viking Therapeutics, Inc. is a clinical-stage biopharmaceutical company, which engages in the development of therapies for metabolic and endocrine disorders. The company is headquartered in San Diego, California and currently employs 59 full-time employees. The company went IPO on 2015-04-29. Its clinical programs include VK2735, a novel dual agonist of the glucagon-like peptide 1 and glucose-dependent insulinotropic polypeptide receptors for the potential treatment of various metabolic disorders. The company is evaluating an oral formulation of VK2735 in a Phase II trial. The company is also developing VK2809, a novel, orally available, small molecule selective thyroid hormone receptor beta agonist for the treatment of lipid and metabolic disorders. Its newest program is evaluating a series of internally developed dual amylin and calcitonin receptor agonists for the treatment of obesity and other metabolic disorders. In the rare disease space, it is developing VK0214, a novel, orally available, small molecule selective thyroid hormone receptor beta agonist for the potential treatment of X-linked adrenoleukodystrophy.
Viking Therapeutics appointed Dr. Hubert C. Chen as CMO to strengthen the VK2735 program during its critical late-stage trials, signaling potential growth in investment prospects.
Viking Therapeutics, Inc. is a clinical-stage biopharmaceutical company, which engages in the development of therapies for metabolic and endocrine disorders. The company is headquartered in San Diego, California and currently employs 59 full-time employees. The company went IPO on 2015-04-29. Its clinical programs include VK2735, a novel dual agonist of the glucagon-like peptide 1 and glucose-dependent insulinotropic polypeptide receptors for the potential treatment of various metabolic disorders. The company is evaluating an oral formulation of VK2735 in a Phase II trial. The company is also developing VK2809, a novel, orally available, small molecule selective thyroid hormone receptor beta agonist for the treatment of lipid and metabolic disorders. Its newest program is evaluating a series of internally developed dual amylin and calcitonin receptor agonists for the treatment of obesity and other metabolic disorders. In the rare disease space, it is developing VK0214, a novel, orally available, small molecule selective thyroid hormone receptor beta agonist for the potential treatment of X-linked adrenoleukodystrophy.
Recently from Cashu
Viking Therapeutics Strengthens Leadership with New Chief Medical Officer for Obesity Treatments
Viking Therapeutics appoints a new Chief Medical Officer, enhancing its commitment to innovative therapies for metabolic conditions that impact millions. Dr. Hubert C. Chen, a veteran with over two de…
Viking Therapeutics Advances VK2735 in Obesity Treatment with Key Trials Expected Soon
Viking Therapeutics (Ticker: VKTX) is making strides in the field of obesity therapeutics, with pivotal developments surrounding its investigational drug, VK2735. The company is set to report importan…
Viking Therapeutics' VK2735: Pivotal Obesity Drug Progress Amid Acquisition Speculation and Market Competition.
Viking Therapeutics (Ticker: VKTX) faces a pivotal moment as it advances its promising obesity drug candidate, VK2735, which could significantly reshape the company's long-term prospects in the biopha…
Viking Therapeutics Advances VK2735 Program for Obesity Treatment at European Congress on Obesity
Viking Therapeutics Advances VK2735 Program to Combat Obesity Viking Therapeutics, Inc. (NASDAQ: VKTX), a clinical-stage biopharmaceutical company, is actively advancing its VK2735 program, a novel du…